Clinical trialPhase 3Completed
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- February 2009
- Ended
- December 2015
- Enrollment
- 89 participants
- Sites
- 25
- Primary outcomes
- Adverse Events
- Sponsor type
- Industry
- Results posted
- 17 February 2017
- Last update
- 12 October 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 12 October 2022
- Primary outcome
- Adverse EventsLanreotide Autogel: 40, n = 42Placebo: 46, n = 47Total: 86, n = 89Values: participants with any TEAEsTime frame: Throughout the study until the completion/early discontinuation visit.No analysis posted for this outcome (outcome 1)
- Participants
- Lanreotide Autogel: 101 started, 16 completedPlacebo: 103 started, 9 completed
- Serious adverse events
- Lanreotide Autogel: 11 of 42Placebo: 14 of 47Total: 25 of 89Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. DOI 10.1007/s12020-020-02475-2↗ Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. DOI 10.1530/erc-15-0490↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
1 secondary outcome
- PFS · Progression Free Survival (PFS): Kaplan-Meier Estimate
- Lanreotide Autogel - Randomised Treatme… 154.14 (123.57 to 237.43), n=101; Placebo - Randomised Treatment in Study… 72.00 (48.43 to 84.57), n=103 [median weeks, 95% Confidence Interval]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).
Detailed description public domain (ClinicalTrials.gov)
While somatostatin analogue treatment is the primary medical therapy for patients with hormone related symptoms and is indicated for the treatment of hormone related symptoms in many international countries, there is no reference standard medical therapy for asymptomatic patients. A 96-week study (Study 2-55-52030-726 (726), NCT00353496) was conducted to investigate the effect of lanreotide Autogel on progression free survival (PFS) in patients with well or moderately differentiated nonfunctioning enteropancreatic NET. While Study 726 was ongoing, the sponsor considered that therapy with lanreotide Autogel should continue to be an option to patients with stable disease at the end of the 96-week treatment period. This extension study was therefore initiated (Study 2-55-52030-729 (729)) which investigated the long term safety of treatment with lanreotide Autogel and enabled investigators to continue to treat their patients who had stable disease, as well as to treat placebo patients who experienced disease progression during the initial 96-week study (Study 726).
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Adverse Events [Throughout the study until the completion/early discontinuation visit.]. Number, participants with any TEAEs. Lanreotide Autogel (n=42): 40; Placebo (n=47): 46; Total (n=89): 86.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression Free Survival (PFS): Kaplan-Meier Estimate [Throughout the study (every 24 weeks and at completion/withdrawal visit)]. Median, weeks (95% Confidence Interval). Lanreotide Autogel - Randomised Treatment in Study 726 (n=101): 154.14 (123.57 to 237.43); Placebo - Randomised Treatment in Study 726 (n=103): 72.00 (48.43 to 84.57).
Papers 2
- Registry-listed results paperLanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label … DOI 10.1007/s12020-020-02475-2↗
- Registry-listed results paperAnti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extensi… DOI 10.1530/erc-15-0490↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.